Coegin Pharma

Coegin Pharma pioneers treatments for skin conditions and rare cancers, achieving a 40% reduction in tumor size in phase II trials, faster than the average oncology startup. Their lead drug candidate targets a niche market with projected annual sales of $200 million by 2027, a figure 25% higher than the #10-ranked biotech peer. Backed by €15 million in venture funding, this Dutch biotech startup leverages proprietary lipid nanoparticle technology to deliver precision therapies with minimal side effects.